Evidence availability for 1-year obesity treatment-initiation decisions: an estimand-aligned Bayesian longitudinal network meta-analysis
Higher doses of obesity pharmacotherapy, such as retatrutide 12 mg, can lead to significant weight loss, but the evidence for long-term treatment decisions is still limited.
Where it sits
this study against the rest of the retatrutide (ly3437943) corpusSummary and findings
This study assessed 1-year weight reduction and discontinuation rates for obesity pharmacotherapy in adults with overweight or obesity. Retatrutide 12 mg showed a placebo-adjusted weight reduction of -19.80 percentage points at 52 weeks. The study included 81,014 participants across 178 trials.
Abstract
<h4>Background: </h4> Obesity pharmacotherapy strategies differ in maintenance dose, titration, and lifestyle support, but existing syntheses primarily compare drugs rather than treatment-initiation decisions. We assessed 1-year weight reduction, permanent discontinuation, and incremental dose-related trade-offs while mapping the availability of eligible trial evidence. Methods We searched eight databases and two trial registries through October 2026 for randomised trials (at least 12 weeks) of obesity pharmacotherapy initiation in adults with overweight or obesity. Maintenance, withdrawal, and switching trials were excluded. Two reviewers independently selected studies, extracted data, and assessed bias and certainty. Bayesian longitudinal network meta-analysis estimated treatment-policy-compatible weight change at 52 weeks. Additional analyses examined discontinuation, dose escalation, titration, lifestyle support, and diabetes-related attenuation. The study was registered with PROSPERO (CRD420261532130). Findings We included 180 reports from 178 trials (196 randomisation units; 81,014 participants). Only 78 units reached the 1-year evidence layer, 50 informed the primary longitudinal model in adults without diabetes, and 45 of 160 target strategies had non-extrapolated 52-week estimates. Placebo-adjusted weight reductions were greatest with retatrutide 12 mg (-19.80 percentage points, 95% CrI -21.81 to -17.78), tirzepatide 15 mg (-16.87, -18.07 to -15.51), and cagrilintide-semaglutide 2.4/2.4 mg (-16.37, -18.10 to -14.70). Only tirzepatide 15 mg and semaglutide 2.4 mg had high-certainty evidence. Thirteen of 32 strategies increased adverse-event-related permanent discontinuation versus placebo; none increased all-cause discontinuation. Five of 22 adjacent dose steps had at least 0.80 probability of adding more than 2 percentage points of weight reduction. Eight 1-year titration contrasts and three trials of randomised lifestyle-support increments were identified. Weight reduction in adults with type 2 diabetes was 62% of that without diabetes (ratio 0.62, 95% CI 0.58-0.66). Interpretation Evidence directly supporting 1-year obesity treatment-initiation decisions remains limited. Higher-dose and multi-receptor strategies achieve substantial weight reduction, but certainty and discontinuation trade-offs vary. Better treatment-policy reporting and randomised evidence on titration and lifestyle support are needed.
Background
This paper addresses the clinical question of how different obesity pharmacotherapy strategies impact treatment-initiation decisions over a one-year period. Prior syntheses have primarily compared drugs rather than focusing on the initiation of treatment. This study is significant as it aims to provide a clearer understanding of weight reduction outcomes and discontinuation rates associated with various pharmacotherapies.
Methods
The study utilized a Bayesian longitudinal network meta-analysis design, including randomised trials of obesity pharmacotherapy initiation in adults with overweight or obesity. A total of 81,014 participants were involved across 178 trials, with a focus on trials lasting at least 12 weeks. Primary outcome measures included weight change at 52 weeks, while secondary outcomes included discontinuation rates and dose-related trade-offs.
Results
The primary endpoint showed a placebo-adjusted weight reduction of -19.80 percentage points for retatrutide 12 mg at 52 weeks, with a 95% credible interval of -21.81 to -17.78. The analysis also reported that 62% of weight reduction was observed in adults with type 2 diabetes compared to those without diabetes, with a ratio of 0.62 and a 95% CI of 0.58-0.66.
Interpretation
The findings indicate that higher-dose and multi-receptor strategies can achieve substantial weight reductions, although the certainty of evidence and trade-offs related to discontinuation vary. Compared to prior literature, the effect size for retatrutide appears significant, but the clinical relevance may be limited by the small number of studies reaching the 1-year evidence layer. Confounding factors include the exclusion of certain trial types and the reliance on a Bayesian analysis framework.
Key findings
- -19.80 percentage points weight reduction with retatrutide 12 mg vs placebo at 52 weeks, 95% CrI -21.81 to -17.78.
- -16.87 percentage points weight reduction with tirzepatide 15 mg vs placebo at 52 weeks, 95% CrI -18.07 to -15.51.
- -16.37 percentage points weight reduction with cagrilintide-semaglutide 2.4/2.4 mg vs placebo at 52 weeks, 95% CrI -18.10 to -14.70.
- 62% of weight reduction in adults with type 2 diabetes compared to those without diabetes, ratio 0.62, 95% CI 0.58-0.66.
- Only 78 randomisation units reached the 1-year evidence layer.
Limitations
- Only 78 randomisation units reached the 1-year evidence layer.
- Excluded maintenance, withdrawal, and switching trials.
- Limited high-certainty evidence for some pharmacotherapies.
- Focus on short-term outcomes may not reflect long-term efficacy.